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Tubulin-binding cofactor (TBC)-B is implicated in the presentation of
a-tubulin ready to polymerize, and at the correct levels to form microtu-
bules. Bioinformatics analyses, including secondary structure prediction,
CD, and crystallography, were combined to characterize the molecular
architecture of Trypanosoma brucei TBC-B. An efficient recombinant
expression system was prepared, material-purified, and characterized by
CD. Extensive crystallization screening, allied with the use of limited prote-
olysis, led to structures of the N-terminal ubiquitin-like and C-terminal cyto-
skeleton-associated protein with glycine-rich segment domains at 2.35-A and
1.6-A resolution, respectively. These are compact globular domains that
appear to be linked by a flexible segment. The ubiquitin-like domain con-
tains two lysines that are spatially conserved with residues known to partici-
pate in ubiquitinylation, and so may represent a module that, through
covalent attachment, regulates the signalling and/or protein degradation
associated with the control of microtubule assembly, catastrophe, or func-
tion. The TBC-B C-terminal cytoskeleton-associated protein with glycine-
rich segment domain, a known tubulin-binding structure, is the only such
domain encoded by the T. brucei genome. Interestingly, in the crystal struc-
ture, the peptide-binding groove of this domain forms intermolecular con-
tacts with the C-terminus of a symmetry-related molecule, an association
that may mimic interactions with the C-terminus of a-tubulin or other physi-
ologically relevant partners. The interaction of TBC-B with the a-tubulin
C-terminus may, in particular, protect from post-translational modifications,
or simply assist in the shepherding of the protein into polymerization.‘
Introduction
Key to the regulation of many biological processes is
the tight control exercised over protein biosynthesis,
folding, and degradation. With respect to tubulin, a
central component of the cytoskeleton, the correct
folding and polymerization involves distinct stages that
are influenced by several chaperones or cofactors [1,2].
Initially, after a tubulin polypeptide is produced, it is
captured by prefoldin [3] and subsequently passed to
chaperonin-containing T-complex polypeptide 1 (CCT)
[4]. When released from CCT, tubulin is essentially
folded, but appears to be unable to polymerize and
form microtubules (MTs) [1]. Our understanding of
what occurs between release from CCT and MT for-
mation is limited. Five tubulin-binding cofactors
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(TBCs) are implicated in late-stage tubulin folding and
heterodimer assembly [1,5–10]. TBC-B and TBC-E are
implicated in binding a-tubulin, whereas TBC-A and
TBC-D interact with b-tubulin. TBC-C is involved in
the final stages of dimer formation, stimulating GTP
hydrolysis in b-tubulin and heterodimer release from a
protein assembly [2]. Little is known about the
molecular basis for the roles of these cofactors, a point
that we sought to address in relation to TBC-B.
TBC-B comprises an N-terminal ubiquitin-like (Ubl)
domain and a C-terminal cytoskeleton-associated pro-
tein with glycine-rich segment (CAP-Gly) domain.
There are NMR structures of the TBC-B Ubl domains
from Caenorhabditis elegans [11], Drosophila melanog-
aster [Protein Data bank (PDB) code 2KJR], Arabid-
opsis thaliana (2KJ6), and Mus musculus (1V6E). The
mouse TBC-B CAP-Gly domain NMR structure has
also been determined (1WHG), but the only crystal
structure known is that of the C. elegans TBC-B CAP-
Gly domain [12]. We targeted the protein from
Trypanosoma brucei, an organism that is considered to
be a useful model for the study of MT biology [13].
Searching against the translated T. brucei genome
(http://www.genedb.org/) with mouse, human and
C. elegans TBC-B sequences identified a single protein,
Tb10.61.2930, with ~ 40% amino acid sequence iden-
tity. This protein, T. brucei TBC-B (TbTBC-B), con-
sists of 232 amino acids organized into the N-terminal
Ubl domain (~ 90 residues) and a CAP-Gly domain
(residues 157–222; Fig. 1).
We now report the construction of an efficient bac-
terial recombinant expression system, protein purifica-
tion and the use of CD and bioinformatics approaches
to investigate secondary structure content and pre-
dicted flexibility. Crystallization of the full-length pro-
tein was achieved, but the samples were poorly
ordered. Consequently, structural analyses of the indi-
vidual domains were carried out. The fortuitous obser-
vation in the crystal structure of the CAP-Gly domain
of intermolecular contacts with the C-terminus of a
symmetry-related molecule suggests how interactions
with partners, including a-tubulin, might occur.
Comparisons with ubiquitin suggest a functional link
between the structure of TBC-B and the regulation of
distinct populations of proteins associated with tubulin
biology by proteasome-dependent degradation.
Results and Discussion
Recombinant full-length TbTBC-B was produced in
Escherichia coli and purified. The final step in purifica-
tion was size exclusion gel chromatography, and this
indicated that the full-length protein is monomeric in
solution. The protein crystallized readily; however,
despite displaying a good appearance (data not
shown), X-ray diffraction from the crystals did not
extend beyond 7 A of resolution. Limited proteolysis
produced two polypeptides, one of which, the Ubl
domain, gave highly ordered crystals, and the structure
was solved with anomalous dispersion methods [14].
Subsequently, crystals of the CAP-Gly domain were
also obtained after testing of a series of truncated con-
structs and molecular replacement allowed for struc-
ture solution. We note, that following proteolysis, the
two domains were readily separated and purified, indi-
cating that there was no domain–domain association,
and when studied individually they remained mono-
meric in solution.
The Ubl domain
The N-terminal Ubl domain of TbTBC-B crystallized
in the tetragonal space group P41212 with a single
polypeptide in the asymmetric unit. Size exclusion
chromatography employed during purification indi-
cated that the protein was monomeric in solution.
The Ubl domain is a small globular entity consist-
ing of a mixed four-strand b-sheet that forms a con-
cave groove in which a single a-helix is placed
(Fig. 2). This is an example of a b-grasp fold, a com-
mon structure involved in protein–protein interactions
[5,11]. A pronounced hydrophobic core is present,
formed mainly by aliphatic side chains. The residues
involved, which have < 10% solvent-accessible surface
area, include Val4, Val6, Leu8, Tyr22, Ile28, Ile31,
Val35, Thr41, Met46, Leu48, Leu50, Met62, Leu68,
Cys73, Ile79, and Val81 (not shown). These core resi-
dues are, in general, conserved among the TBC-B
family of proteins. The surface residues are more vari-
able, perhaps indicative of a module that does not
interact directly with a-tubulin. Note that, as a-tubu-
lin is a very highly conserved protein, any interacting
components would be expected to display conserva-
tion on their surfaces if they interacted at similar
positions.
Fig. 1. Schematic of TbTBC-B. Domains and termini are labelled.
Residues 3–87 and 157–222 represent the assigned Ubl (blue box)
and CAP-Gly (yellow box) domains, respectively. Black lines and
residue numbers 2–87 and 153–232 represent the structures
determined.
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The Ubl module, in terms of amino acid sequence,
is the more variable domain of TBC-B (Fig. 3) as
compared with homologues. For example, the Ubl and
CAP-Gly domains of T. brucei and mouse TBC-Bs
share ~ 30% and 55% sequence identity, respectively.
Although remarkably similar in structure to ubiquitin
(rmsd of 0.83 A over 41 Ca atoms with PDB
code 1UBQ), the TbTBC-B Ubl domain shares only
10% sequence identity. Ubiquitin contains seven
lysines (residues 6, 11, 27, 29, 33, 48, and 63) that are
targets for covalent modification [15,16]. Intriguingly,
and despite only low sequence conservation, the Ubl
domain of TbTBC-B contains two lysines (Lys34 and
Lys62), which correspond to Lys27 and Lys48 of
ubiquitin, and a structural overlay reveals strong struc-
tural similarity in terms of the positioning of these res-
idues (Fig. 4). The Ubl domains of known structure
overlap at a similar level (Fig. 5A).
The CAP-Gly domain
Crystals of the CAP-Gly domain of TbTBC-B were
obtained from a construct producing the 81 C-terminal
amino acids. The peptide eluted from the size exclu-
sion column as a single species of ~ 11 kDa, indicating
a monomer in solution. The crystals are orthorhombic
with space group P212121, with two polypeptides,
labelled A and B, in the asymmetric unit. The rmsd
observed after superposition of 79 Ca positions of
molecule A on molecule B was 0.86 A. No restraints
were imposed on noncrystallographic symmetry during
refinement, so this indicates that the molecules are
highly similar. The numbering of residues and second-
ary structure elements in the C-terminal domain is car-
ried on from the Ubl domain.
Although the sequence derived from the genome
assigns residue 223 as aspartate, the cloned gene
encodes a glutamate at this position, an observation
confirmed by the structural analysis. This conservative
difference could be an artefact of the cloning process,
or, more likely, could result from a natural variation
in the strain that from which genomic DNA was
obtained. We note that the T. brucei gambiense gene
sequence for TBC-B (http://www.genedb.org/) encodes
a glutamate in this position.
The TbTBC-B CAP-Gly domain is a small globular
structure with a similar fold to other CAP-Gly
domains, and is an important module for the recogni-
tion and binding of the C-terminal tail of a-tubulin
[17,18]. Structural comparison reveals that TbTBC-B
matches closely to other CAP-Gly domains (Fig. 5B).
The C. elegans TBC-B CAP-Gly domain, which
shares ~ 50% sequence identity, is the closest struc-
Fig. 2. Ribbon diagram of the two domains of TbTBC-B. The Ubl
domain b-strands are in light blue, a-helices are in pink, and the
CAP-Gly domain b-strands are in yellow. The N-termini and
C-termini and elements of secondary structure are labelled. The
orientation of the two domains with respect to each other is
arbitrary. Two lysines of note are depicted as pink spheres.
Fig. 3. The primary and secondary structure of TbTBC-B. Residues strictly conserved in at least 75% of TBC-B sequences are encased in
black. Red stars mark Lys32 and Lys60, which are conserved in ubiquitin.
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tural relative, with an rmsd of 1.4 A for 95 Ca atoms.
The fold is dominated by five b-strands, b5–b9, form-
ing a consecutive twisted antiparallel sheet with b9
returning to lie in an antiparallel fashion at the other
side of b5. The side of strand b8 forms the floor of a
solvent-exposed, primarily basic groove, which is
flanked by the two extended loops, linking b6 and b7,
and b7 and b8. NMR studies have revealed that the
a-tubulin C-terminal tail peptide binds to this groove
in the CAP-Gly domain of human CAP-Gly domain
containing linker protein 170 (CLIP-170) [19]. Several
glycines (residues 170, 188, 195, 200, 215, and 225),
which are responsible for the name of this domain,
are highly conserved and contribute to the fold of the
domain [17]. Residues around the peptide-binding
groove are also highly conserved, Phe216, Leu180,
Trp185, Val201 and Phe207 forming a hydrophobic
core that helps to stabilize the floor of the groove.
On the other side of the domain from the peptide-
binding groove, there are two salt bridges formed by
Arg159 with Asp191, and Arg172 with Glu189, which
link b5 with b7, and b6 with b7, respectively. In addi-
tion, hydrogen bonds between Arg159 and the
backbone oxygen of Phe227 link b5 to the C-terminal
segment of b9 (Fig. 6).
CAP-Gly domains, including those of TBC-B, pos-
sess a highly conserved pentapeptide tubulin-binding
motif with a sequence that is almost always GKNDG
[19,20]. This motif is placed on one of the loops that
flank the peptide-binding groove. NMR studies of
CLIP-170 indicate that the asparagine at position 3
can participate in hydrogen bond formation with the
C-terminal tail of peptides ending with the sequence
EE[Y/F]. This is the sequence found at the C-terminus
of a-tubulin and several MT tip-binding proteins.
Occasionally, the asparagine in the tubulin-binding
motif is replaced by a histidine, a conservative change
that does not affect peptide binding. However, mutat-
ing either the lysine or the asparagine to alanine has a
deleterious effect on binding [20]. The TbTBC-B CAP-
Gly domain has a different sequence in this tubulin-
binding motif at residues 195–199, GKGDG. Glycine
rather than asparagine occupies the third position, and
this nonconservative change precludes the formation
of a side chain hydrogen bond with the terminal resi-
due of an EE[Y/F] peptide.
No crystal structures have been solved with an a-
tubulin tail-like ligand bound to TBC-B, and, despite
our efforts, it was not possible to cocrystallize the
TbTBC-B CAP-Gly domain with peptides either. How-
ever, and fortuitously, in our structure the C-terminus
Fig. 4. Structural overlay of TbTBC-B Ubl (blue) and ubiquitin (PDB
code 1UBQ; pink). Spatially conserved lysines are depicted as
sticks.
Fig. 5. (A) The TbTBC-B Ubl domain superimposed with other
TBC-B Ubl structures. Structures are shown as tubes coloured by
structure: yellow, TbTBC-B; cyan, C. elegans; magenta,
D. melanogaster; slate, M. musculus. Affinity tags, where present,
have been omitted from the models. The N-terminus is at the top,
and the C-terminus points to the bottom. (B) The TbTBC-B CAP-Gly
domain superimposed on other TBC-B CAP-Gly domains, in a
similar way as in (A): yellow, TbTBC-B; cyan, C. elegans; pink,
M. musculus. The N-terminus is on the left side, and the
C-terminus is on the right.
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of chain A forms intermolecular contacts with the
basic groove of a symmetry-related chain B (Fig. 7A).
The symmetry operation is ( x + 1/2,  y, z + 1/2).
The loss of these intermolecular contacts may help to
explain why constructs in which the C-terminus had
been truncated did not crystallize. The C-terminus of
TbTBC-B has the sequence EVF, which is similar to
the a-tubulin tail EE[Y/F] motif, and so these intermo-
lecular interactions can be taken to mimic the associa-
tion with a relevant binding partner. The terminal
residue of chain A, Phe232, anchors the peptide in the
groove with a combination of hydrophobic and hydro-
philic interactions. The aromatic side chain interacts
with a hydrophobic patch consisting of the chain B
residues Leu180, Val201, and Phe216. The carboxylate
of this terminal residue forms a hydrogen bond with
the main chain amide of Phe216, and participates in a
water-mediated hydrogen-bonding network with
Asp198 and Thr200. The C-terminal peptide then
arches away from b8, trailing back to Glu230, which
forms a salt bridge with Arg167. Another residue,
Gln221, interacts with Glu230, as well as contributing
to a water-mediated interaction with the backbone of
Pro228. Gln221 is conserved in the trypanosomatid
TBC-B sequences, but is highly variable in other spe-
cies. The final interaction that chain A undergoes as it
exits the groove is a salt bridge between Asp226 and
Arg218.
A
B
Fig. 6. The Asp191 and Arg159 salt bridge in the CAP-Gly domain.
The main a trace is shown as grey sticks. Hydrogen bonds are
shown as black dashed lines. Conserved residues are shown as
sticks coloured by atom type: C, grey; N, blue; O, red, S, yellow.
A
B
Fig. 7. (A) Chain A C-terminus interacting with the peptide-binding
groove of a symmetry-related molecule, chain B. The chain B main
chain is shown in grey ribbon style, and residues that surround the
C-terminal tail are shown as sticks coloured according to atom
type: C, grey; N, blue; O, red. Chain A is shown as sticks coloured
according to atom type: C, slate blue; O, red. Hydrogen bonds are
shown as black dashed lines. Residue numbers for chain A are
shown in cyan. L217 and Q221 (chain B) and V231 (chain A) are
shown with two side chain rotamer conformations. G199 and F216
are not labelled. (B) Relative positions of the C-terminus peptides
in M. musculus CAP-Gly domain II of CLIP-170 structure (pale pink
cartoon; peptide carbon atoms are in magenta) and TbTBC-B
(chain B as a white cartoon; chain A carbon atoms are in slate). For
both peptides: O, red; N, dark blue. Amino acids, for clarity, are
shown as backbones, except for proline and the C-terminus
residues. Peptides are labelled 1–3 from the C-terminus: A for
TbTBC-B chain A; P for M. musculus polypeptide.
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The NMR structure of the CAP-Gly domain of
human CLIP-170 complexed with an a-tubulin tail
peptide provides an example for comparative purposes
[20]. The domains share ~ 50% identity and are struc-
turally well conserved, with an rmsd of 1.06 A over 50
Ca atoms. In the CLIP-170 a-tubulin tail peptide com-
plex, the peptide is positioned closer to the b8 strand
(Fig. 7B).
The Gly/Asp difference at position 4 in the tubulin-
binding loop, discussed earlier, allows the C-terminus
of chain A to bind further along the groove than the
a-tubulin tail peptide in the CLIP-170 structure. This
causes a relative shift in the position of the Val231 side
chain, which is directed out of the groove, and under-
goes no interactions with the CAP-Gly domain. The
third residue from the end of chain A, Glu230 (A3 in
Fig. 7), is in the same position as the second residue
from the end in the a-tubulin tail peptide, Glu450 (P2
in Fig. 7). This may explain why the sequence EVF
can bind, contrary to the conclusion that EE[Y/F] is
the essential recognition sequence [18,19]. In an
attempt to further investigate CAP-Gly peptide inter-
actions, we carried out isothermal titration calorimetry
(ITC) with the hexapeptide EDVEEY, which repre-
sents the C-terminal residues of T. brucei a-tubulin. A
range of concentrations of the protein domain and the
peptide were tested, but no heat changes were
observed (data not shown).
The peptide-binding groove on chain A is occupied
by two formate molecules, derived from the crystalliza-
tion mixture, which bind in similar fashion to the neg-
atively charged moieties of the C-terminal peptide just
discussed (data not shown). One formate interacts with
Arg167 and the other with Gln221.
Unique features of Trypanosoma TBC-B
CAP-Gly domains recognize the highly conserved
a-tubulin C-terminal tail with the sequence EE[Y/F]
[18]. In T. cruzi and Trypanosoma vivax a-tubulin, this
sequence is matched exactly. In T. brucei gambiense
and T. brucei 427, the sequence is EMF, and, as just
described, we present structural data to show that the
sequence EVF can also bind to a CAP-Gly domain.
Our structure of TbTBC-B indicates that the penulti-
mate residue, whether glutamate or methionine, is
probably directed out of the peptide-binding groove,
and, with no direct interactions involving the side
chain, the identity would appear to be less important
for binding.
Both TBC-B and TBC-E retain highly conserved
CAP-Gly domains across numerous different species,
and this probably reflects important roles in tubulin
biology [20]. The CAP-Gly domain of TBC-E also
usually contains the GKNDG tubulin-binding motif.
The closest homologue to human TBC-E in T. brucei
is Tb927.3.2680, a 530-residue protein with ~ 25%
sequence identity. The protozoan protein contains a
leucine-rich repeat segment and a Ubl domain but,
surprisingly, lacks a CAP-Gly domain. In fission yeast,
the TBC-E homologue Alp21 also lacks a CAP-Gly
domain, but is indispensible for maintaining a-tubulin
levels, MT integrity, and cell survival [21,22]. In con-
trast, mammals possess a TBC-E paralogue, which
lacks the CAP-Gly domain. This protein, known as
E-like, with ~ 30% sequence identity with TBC-E, can-
not compensate for loss of TBC-E, and, instead of
being involved in tubulin biogenesis, is implicated in
degradation [23]. This difference is perhaps a legacy of
a more complex and highly regulated tubulin biology
in higher eukaryotes, and suggests that a degree of
care is required when considering different model sys-
tems.
We could not identify any other CAP-Gly domains
encoded by the T. brucei genome, even in proteins that
usually contain such modules, e.g. kinesins. Perhaps,
in trypanosomatids, TBC-B is sufficient to provide this
interaction with the a-tubulin tail, or other modules,
yet to be discovered, may compensate for this func-
tion.
The missing structural information
As it was not possible to obtain crystallographic data
on the linker region between the globular domains
(residues 89–153), the CD spectrum of full-length
TBC-B was analysed. The spectra indicated a low
a-helical content of ~ 10% and a b-strand content of
~ 35%. The a-helical content of the Ubl domain itself
is ~ 8% of the overall structure, and, together with the
prediction of a short helical segment between resi-
dues 116 and 123, ~ 4% of the sequence, there is
excellent agreement with the CD data. Residues with a
b-strand conformation constitute nearly 30% of the
full-length structure, which is also in good agreement
with the spectroscopic data. Both the CD results and
the structural analyses also agreed well with the pre-
dicted secondary structure, and overall indicate a two-
domain structure with a flexible linker.
Functional implications and concluding remarks
Structures of the Ubl and CAP-Gly domains of
TbTBC-B, the first such protist structures, were deter-
mined to 2.3-A and 1.6-A resolution, respectively. It
was not possible to solve the full-length structure, as
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the crystals did not diffract sufficiently well, and
attempts to extend structural information into the
region linking the two domains were also unsuccessful.
It was determined that the missing linker region is
mostly unstructured, with only a short segment of
a-helix being noted, and potentially flexible.
The fold of the Ubl domain is highly conserved,
despite low sequence identity within TBC-B proteins
and, indeed, ubiquitin itself. A striking similarity is
observed in the spatial location of two functionally
important lysines in ubiquitin, and strongly supports a
biological function for the Ubl domain, and by impli-
cation for TBC-B. Through reversible post-transla-
tional modification, TBC-B can influence aspects of
tubulin biology in a proteasome-dependent manner.
Such a conclusion is consistent with other studies.
Yeast two-hybrid studies suggest that proteasome-
dependent degradation of human TBC-B is driven by
gigaxonin binding to the Ubl domain [24]. In addition,
Saccharomyces cerevisiae TBC-E interacts with the
ubiquitin receptor Rpn10 via the Ubl domain, and
subsequently with a ubiquitin ligase complex, provid-
ing a route to protein degradation [10]. We note also
that Lys34, but not Lys62, of TbTBC-B is conserved
in the Ubl domains of TBC-E (data not shown).
In the final stages of MT assembly, a-tubulin and
b-tubulin form a heterodimer with the encouragement
of the TBC proteins. A balance has to be struck
between the availability of free tubulin, heterodimer
assembly, and release of MT structures. This process
involves a number of highly abundant proteins, and
the presence of Ubl domains offers a means whereby
protein folding and the population of complex assem-
blies can be regulated by protein degradation or recy-
cling. The use of a Ubl protein rather than ubiquitin
itself may provide specificity with regard to this aspect
of tubulin biology. Cognate activating enzymes might
then contribute to the regulation of levels of free tubu-
lin heterodimers, tubulin polymerization, and MT
catastrophe, or to avoid miscommunication during a
stress response. It will therefore be of great interest to
now identify, from a plethora of candidates, the spe-
cific ligases and proteases that might participate in the
control of MT disassembly/assembly as opposed to
other biological functions.
The molecular packing in the crystal structure of the
CAP-Gly domain places the C-terminal tail of one
CAP-Gly domain in the peptide-binding groove of a
symmetry-related molecule, and allows examination of
interactions in this binding site. The binding differs
slightly from that observed in a CLIP-170 CAP-Gly
domain bound to an a-tubulin tail peptide, owing to a
difference in the b7–b8 tubulin-binding loop of
TbTBC-B. A glycine replaces asparagine at position 3
of the normally conserved GKNDG sequence, and
allows the C-terminus of chain A to bind further down
in the peptide-binding groove. This appears to be a
trypanosomatid-specific feature.
Tubulin and MT assembly are subject to C-terminal
post-translational modifications, which provide impor-
tant tracking positions for a range of MT-binding
partners [25]. For example, the C-terminal residue of
a-tubulin is a tyrosine that can be removed and then
replaced, and adjacent glutamates can be polyglutamy-
lated or, in some species, polyglycylated. The consen-
sus sequence for recognition by CAP-Gly domains has
been deduced as EE[Y/F], and proteolytic removal of
the tyrosine prevents such recognition of a-tubulin
[25]. This provides a feature that might be used to reg-
ulate subpopulations of MTs. A plausible function of
the CAP-Gly domain may therefore be to bind then
block post-translational modifications of the C-termi-
nal tyrosine, as the complex with a-tubulin appears to
form even while it is still bound to CCT [8], i.e. while
the tyrosine is still present.
We were unable to observe any binding of the CAP-
Gly domain with a hexapeptide representing the termi-
nal residues of T. brucei a-tubulin by using ITC.
According to previous work, the presence of TBC-E
might be required for TBC-B to form a stable complex
with a-tubulin [6]. Further experiments would be
required to inform hypotheses involving the need for
partner proteins and/or post-translational modifica-
tions that allow TBC-B to contribute to MT assembly
or disassembly.
Experimental procedures
Protein production and purification
The gene encoding full-length TbTBC-B was amplified from
genomic DNA (strain 927) with 5′-CATATGTCCGTTG
TTAAAGTATCGC-3′ and 5′-CTCGAGTTAAAACACCT
CCGGGGGAAAGTC-3′ as forward and reverse primers,
respectively (ThermoFisher Scientific, Waltham, MA,
USA). The restriction enzyme sites for NdeI and XhoI are
in bold. The PCR product was ligated into pCR2.1-TOPO
with the TOPO TA Cloning Kit (Invitrogen, Carlsbad, CA,
USA), and then cloned into a modified pET15b (Novagen,
Madison, WI, USA) expression vector, which adds an N-
terminal His6 tag and a tobacco etch virus (TEV) protease
cleavage site to the product. Sequencing confirmed the
identity of the construct, and the vector was heat-shock-
transformed into E. coli Rosetta (DE3) pLysS cells for
expression. DNA encoding the CAP-Gly domain, resi-
dues 157–222, was amplified from the vector containing the
FEBS Journal (2013) © 2013 FEBS 7
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TbTBC-B gene with 5′-CATATGGCAGAGACAATACA
TGTGGGGG-3′ and 5′-CTCGAGTTAAAACACCTCCG
GGGGAAAGTC-3′ as forward and reverse primers,
respectively (ThermoFisher Scientific). The gene fragment
was cloned into the modified pET15b vector as described
above, and transformed into E. coli Rosetta (DE3) pLysS
cells for protein production.
Similar protocols were applied to purify full-length
TbTBC-B and the CAP-Gly domain. Typically, cells were
grown at 37 °C in 1 L of LB medium supplemented with car-
benicillin (50 lgL1) and chloramphenicol (25 lgL1).
Gene expression was induced, at a D600 nm of 0.6, by addition
of 1 mM isopropyl thio-b-D-galactoside. The culture was incu-
bated for a further 16 h at 22 °C, and cells were then har-
vested by centrifugation at 3500 g for 30 min at 4 °C. The
cells were resuspended in a lysis buffer (50 mM Tris/HCl,
pH 7.5, 250 mMNaCl, 25 mM imidazole) containing DNase I
and EDTA-free protease inhibitors (Roche, Basel, Switzer-
land), and then lysed with a French press at 16000 p.s.i. The
resultant lysate was centrifuged at 35 000 g for 30 min at
4 °C, and the supernatant was loaded onto a pre-equilibrated
HisTrap HP 5-mL column (GE Healthcare, Milwaukee, WI,
USA) precharged with Ni2+. A linear gradient of 25 mM to
1 M imidazole was applied to elute the proteins, and the
derived fractions were analysed by SDS/PAGE. Samples were
pooled and incubated with His-tagged TEV protease at 30 °C
for 3 h, and then dialyzed into 50 mM Tris/HCl (pH 7.5) and
250 mM NaCl. The sample was loaded onto a HisTrap HP 5-
mL column to remove the His-tagged TEV protease, unc-
leaved product, and histidine-rich contaminants. A Super-
dex 20 026/60 size exclusion column (GE Healthcare)
equilibrated with 50 mM Tris/HCl (pH 7.5) and 250 mM
NaCl was used to further purify the protein. This column had
been calibrated with BioRad Gel Filtration standards. Frac-
tions containing the proteins were pooled and concentrated to
10 mgL1 with Amicon Ultra devices (Millipore) for subse-
quent use. The purity and identity of the proteins were con-
firmed by MALDI-TOF MS. Yields of ~ 20 mgL1 cell
culture for full-length TBC-B and ~ 8 mgL1 cell culture for
the CAP-Gly domain were obtained.
A series of constructs encoding five polypeptide frag-
ments, covering residues 91–232, 101–232, 113–232, 128–
226, and 143–232, were also produced in an attempt to
extend structural knowledge between the domains. These
polypeptides proved to be either insoluble or failed to crys-
tallize, and so no further details are provided.
CD of full-length TbTBC-B
CD spectra were recorded on a Jasco J-810 spectropolarim-
eter. Far-UV CD spectra were obtained with 0.5 mgmL1
protein solutions and a 0.02-cm-pathlength quartz cuvette.
Five scans were accumulated and averaged with the follow-
ing parameters: scan rate, 50 nmmin1; response, 0.5 s;
and bandwidth, 1 nm. Protein CD spectra were corrected
by subtracting the appropriate buffer spectrum and correct-
ing for protein concentration. Protein secondary structure
estimates were obtained with the CONTIN procedure [26],
available from the DICHROWEB server [27].
Analysis of crystals formed following proteolysis
Crystals of the full-length protein did not diffract beyond
~ 7-A resolution (data not shown). Limited proteolysis by
addition of chymotrypsin to the crystallization drops [28]
was therefore tested in the search for ordered crystals. Crys-
tals were observed in a number of conditions, one of which
was successfully optimized, as detailed below. These crystals
were harvested, washed in the reservoir solution, dissolved
in ddH2O, and then submitted for MALDI-TOF MS analy-
sis. This gave a molecular mass of 12 069 Da for the poly-
peptide. The fragment was isolated by SDS/PAGE and then
transferred onto a poly(vinylidene difluoride) membrane.
The band was then submitted for N-terminal Edman
sequencing, and the sequence GHMSVVKV was identified.
This corresponds to the N-terminus of TbTBC-B, with the
first two residues being remnants of the TEV cleavage site
after treatment to remove the His6 tag. These data indicated
that the Ubl domain had crystallized.
Isolation of products after chymotrypsin
treatment
Full-length TbTBC-B (50 mg) was incubated with chymo-
trypsin (0.02 mg) overnight, and then dialyzed into 50 mM
Tris/HCl (pH 7.5) and 50 mM NaCl. The mixture was
loaded onto a HiTrap Q HP 5-mL column, and eluted with
a linear gradient of 50 mM to 1 M NaCl. The products of
the cleavage eluted as two peaks, and were analysed by
SDS/PAGE. Sample 1 eluted at 50 mM NaCl, and sam-
ple 2 at 220 mM NaCl. MALDI-TOF MS of sample 1, the
Ubl domain, gave a mass of 12 002 Da, and MALDI-
TOF MS of sample 2 gave a mass of 12 116 Da. Both pro-
tein fragment samples were concentrated to 5 mgmL1.
Selenomethionine (SeMet) derivative of the Ubl
domain
A SeMet-substituted Ubl domain was obtained from mate-
rial generated as described above, and with incorporation
achieved following metabolic inhibition [29]. Purification of
the protein yielded ~ 2 mgL1 of cell culture. Analysis by
MALDI-TOF MS indicated full incorporation of four
SeMet residues.
Crystallization and data collection
Initial crystallization conditions were established by sitting
drop vapour diffusion with a Phoenix Liquid Handling
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System (Rigaku; Art Robins Instruments, Mountain View,
CA, USA) and commercially available screens. Several con-
ditions were optimized for hanging drop vapour diffusion,
with drops of 1 lL of protein solution and 1 lL of reser-
voir.
Rectangular crystals (dimensions 0.3 9 0.1 9 0.1 mm)
of the Ubl domain, which had been isolated after proteoly-
sis of the full-length protein, were obtained with a reservoir
of 0.1 M Hepes (pH 7.5), 1% poly(ethylene glycol) 400, and
2 M ammonium sulfate, and a protein concentration of
2.5 mgmL1. Crystals of the CAP-Gly domain, derived
from expression of a gene fragment, were rod-like, with
dimensions of 1 9 0.05 9 0.05 mm, and were obtained
with reservoir conditions of 0.2 M potassium formate, 30%
poly(ethylene glycol) 3350 and a 7.5 mgmL1 protein solu-
tion in 50 mM Tris/HCl (pH 7.5) and 250 mM NaBr.
Crystals were transferred to a solution containing a mix-
ture of their reservoir solution and 40% poly(ethylene gly-
col) 400 for ~ 15 s before being cooled to 173 °C in
a stream of nitrogen. The crystals were characterized
in-house with a Micromax HF007 copper-rotating anode
X-ray generator equipped with an R-axis IV++ dual image
plate detector. Subsequently, data were collected with
ADSC charge-coupled device detectors at the Diamond
light source beamline I03 for the Ubl domain and at beam-
line I02 for the CAP-Gly domain.
Data from the Ubl domain crystal were processed with
XDS [30] and SCALA [31]. Initial phases were obtained with
SeMet single-wavelength anomalous dispersion methods
[14], with data measured at the experimentally determined f′
maximum wavelength (k = 0.98 A) in the CCP4 pipeline [32]
with CRANK [33]. A figure-of-merit of 0.23 was obtained from
BP3 [34], and this increased to 0.67 after density modification
and solvent flattening in SOLOMON [35]. This phase set was
used for initial model building with BUCCANEER [36].
Data from the CAP-Gly domain crystal were scaled and
processed with IMOSFLM [37] and SCALA [31]. The PHYRE ser-
ver [38] identified the NMR structure of the M. musculus
CAP-Gly domain of TBC-B (PDB code 1WHG), sharing a
sequence identity of ~ 55%, as a suitable model for molec-
ular replacement. A poly-Ala model was prepared with
CHAINSAW [39], and the positions of two molecules were
then identified with PHASER [40]. Rigid body refinement
gave an initial R-factor of 49% to 1.6-A resolution.
Both structures were refined with rounds of map inspec-
tion and model manipulation with COOT [41] and refinement
calculations with REFMAC [42]. When the protein models
were nearly complete, waters and ligands (ethylene glycol in
the Ubl domain and formate in the CAP-Gly domain) were
added, together with multiple conformers for several side
chains. The geometric quality of the models was assessed
with MOLPROBITY [43]. Figures were created with PYMOL [44],
and solvent accessibility analyses were performed with AR-
EAIMOL [32]. Crystallographic statistics are presented in
Table 1. Coordinates and structure factors are deposited
with the PDB under accession codes 4B6W for the Ubl
domain and 4B6M for the Cap-Gly domain.
Bioinformatic analyses
Secondary structure and disorder predictions were obtained
from PHYRE [38] and PSIPRED [45]. Structural comparisons
and homologues were identified with DALI [46]. Conserved
residues within the CAP-Gly domain were identified with
CONSURF [47]. The UniProt reference cluster 90 (UNI-
REF90) [48] database was searched, and sequences were
aligned with MAFFT [49]. Overall, 642 sequences were identi-
fied with PSI BLAST [50], on the basis of sequence identity in
the range 35–95%, 417 of which were unique. A subset of
sequences, 150, the default value in CONSURF, with identity
> 50% were used for comparisons. However, there were
not enough homologues with identities of > 30% of the
Ubl domain for CONSURF to be used, so 31 sequences with
identities in the range 31–38%, were aligned by the use of
MUSCLE [51], and residues with > 75% conservation were
annotated.
Table 1. TbTBC-B domain crystallographic statistics.
Ubl domain CAP-Gly domain
Space group P41212 P212121
Unit cell lengths (A) 50.9, 50.9, 77.2 32.7, 55.7, 80.4
Resolution range (A) 36.00–2.35 40.18–1.59
Completeness (%) 100 (99.8)a 100 (99.97)
<I/r(I)> 15.4 (3.3) 28.2 (9.6)
Reflections measured/
unique
58 686/4631 282 648/20 384
Redundancy 12.7 (9.4) 13.9 (14.1)
Anomalous redundancy: 7.1 (5.0) NA
Rmerge
b 0.12 (0.64) 0.07 (0.28)
Rwork
c/Rfree
d 0.16/0.21 0.20/0.24
Protein residues (chain A/B) 89 79/78
Ligands (number) Ethylene glycol (1) Formate (6)
Rmsd from ideal geometry
Bond lengths (A)/angles (o) 0.015, 1.53 0.01, 1.44
Thermal parameters (B, A2)
Wilson B 42.6 14.6
Mean B (all atoms) 20.1 14.8
Protein atoms (chainA/B) 18.0 12.3/12.5
Ligands 58.9 21.0
Water molecules 42.4 24.8
Ramachandran plot
Favored/allowed (%) 97.6/2.4 98/2
NA, not analysed.
a Values in parentheses refer to the highest-resolution bin.
b Rmerge = ∑h∑i||(h,i)  <I(h)> ∑h∑I I(h,i).
c Rwork = ∑hkl||Fo|–|Fc||/∑|Fo|, where Fo is the observed structure
factor amplitude and Fc is the structure-factor amplitude calculated
from the model.
d Rfree is the same as Rwork except that it was only calculated using
a subset, 5%, of the data that are not included in any refinement
calculations.
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ITC details
ITC experiments were performed at 25 °C with a VP-ITC
calorimeter (MicroCal, Northampton, MA, USA). The 1.4-
mL sample cell and 300-lL syringe were filled with TBC-B
CAP-Gly domain and peptide EDVEEY in a buffer of
50 mM Tris/HCl (pH 7.5) and 250 mM NaCl. Typically,
8 lL of peptide was injected from the stirred syringe
(305 r.p.m.) 30 times into the sample cell. The peptides
were dissolved in the minimum amount of the buffer, and
then diluted to the appropriate concentration just before
use. Four experiments were carried out with CAP-Gly/
hexapeptide concentrations of 1 : 10, 10 : 100, 7 : 500 and
45 : 500 lL. No binding events were observed.
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